Taimei Medical Technology

Taimei Medical Technology is a digital solutions provider for the pharmaceutical and medical-device industry, founded in 2013 and listed on the Hong Kong Stock Exchange in October 2024 under ticker 02576.HK . The company operates TrialOS and PharmaOS, two digital collaboration platforms that connect hospitals, drugmakers, service providers, patients and regulators across clinical-trial design, patient recruitment, data collection and post-market commercialisation . As of March 2024 it served more than 1,400 pharmaceutical companies and CROs, including 21 of the world's top 25 drugmakers and 90 of China's top 100 innovators, and maintained partnerships with over 700 clinical-trial institutions, more than 80% of them tier-three grade-A hospitals .

5Y Capital, which invested in three consecutive funding rounds between 2018 and 2020, described the company as having evolved from a software-product business to an industry collaboration platform and then to a digital-empowered service provider . The firm raised over RMB 1.2 billion in a September 2020 round led by Tencent, Hillhouse Venture Capital and Yunfeng Capital, with follow-on participation from Morningside (now 5Y Capital), Matrix Partners China and others .